Literature DB >> 16781022

Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media.

Y Genzel1, R M Olmer, B Schäfer, U Reichl.   

Abstract

A process for equine influenza virus vaccine production using a microcarrier system (Cytodex 1) in a 2 L Wave bioreactor is described. Growth of Madin Darby canine kidney (MDCK) cells in serum containing GMEM medium (SC) is compared to growth in serum-free Ex-Cell MDCK medium (SF) without washing steps and medium exchange before infection. Cultivations with microcarrier concentrations of 2 and 4 g/L for both media are shown. Metabolic data from carbon and amino acid metabolism are discussed. Additionally, in roller bottle experiments the influence of multiplicity of infection (moi) and trypsin concentration on the HA value was investigated. Analysis of HA and TCID(50) at 37 degrees C showed a stable HA of maximum 2.6 log HA/100 microL for 2 weeks. Peak TCID(50) titers of 10(7.7) viruses/mL were achieved 20h post infection, but infectivity was below detection limit after 150 h. Cell attachment onto microcarriers under serum-free conditions was improved by Ca(2+) addition and by cell harvesting without trypsin using only an EDTA/PBS solution. For the wave cultivation maximum virus titers of 2.3-2.6 log HA units/100 microL were reached from infection with a moi of 0.05. However, in SF medium pH dropped to less than pH 6.8 which resulted in lower HA titers of 1.7 log HA units/100 microL. For the higher microcarrier concentration (4 g/L) medium exchange steps (500 mL) were needed for both media. Omission of the washing step and medium exchange before infection in SF medium clearly simplified the influenza production process; however, for higher virus yields a better pH control of the wave bioreactor would be required. Higher cell densities (2.8 x 10(6) cells/mL for 2 g/L microcarrier) and better attachment compared to stirred tank bioreactors showed, that the wave bioreactor is a good alternative to stirred tank processes for expanding production capacities in case of a pandemic.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16781022     DOI: 10.1016/j.vaccine.2006.05.023

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Suspension culture of human pluripotent stem cells in controlled, stirred bioreactors.

Authors:  Ruth Olmer; Andreas Lange; Sebastian Selzer; Cornelia Kasper; Axel Haverich; Ulrich Martin; Robert Zweigerdt
Journal:  Tissue Eng Part C Methods       Date:  2012-06-04       Impact factor: 3.056

2.  Overcoming nutrient limitations for cell-based production of influenza vaccine.

Authors:  Xu-Ping Liu; Ding Huang; Wen-Song Tan; Jian Luo; Ze Chen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Metabolic effects of influenza virus infection in cultured animal cells: Intra- and extracellular metabolite profiling.

Authors:  Joachim B Ritter; Aljoscha S Wahl; Susann Freund; Yvonne Genzel; Udo Reichl
Journal:  BMC Syst Biol       Date:  2010-05-13

4.  Conversion of MDCK cell line to suspension culture by transfecting with human siat7e gene and its application for influenza virus production.

Authors:  Chia Chu; Vladimir Lugovtsev; Hana Golding; Michael Betenbaugh; Joseph Shiloach
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-17       Impact factor: 11.205

5.  Production of inactivated influenza H5N1 vaccines from MDCK cells in serum-free medium.

Authors:  Alan Yung-Chih Hu; Yu-Fen Tseng; Tsai-Chuan Weng; Chien-Chun Liao; Johnson Wu; Ai-Hsiang Chou; Hsin-Ju Chao; Anna Gu; Janice Chen; Su-Chen Lin; Chia-Hsin Hsiao; Suh-Chin Wu; Pele Chong
Journal:  PLoS One       Date:  2011-01-24       Impact factor: 3.240

6.  Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells.

Authors:  Allen Chen; Swan Li Poh; Christian Dietzsch; Elisabeth Roethl; Mylene L Yan; Say Kong Ng
Journal:  BMC Biotechnol       Date:  2011-08-11       Impact factor: 2.563

7.  Metabolic and kinetic analyses of influenza production in perfusion HEK293 cell culture.

Authors:  Emma Petiot; Danielle Jacob; Stephane Lanthier; Verena Lohr; Sven Ansorge; Amine A Kamen
Journal:  BMC Biotechnol       Date:  2011-09-01       Impact factor: 2.563

8.  Flow cytometric monitoring of influenza A virus infection in MDCK cells during vaccine production.

Authors:  Josef Schulze-Horsel; Yvonne Genzel; Udo Reichl
Journal:  BMC Biotechnol       Date:  2008-04-30       Impact factor: 2.563

Review 9.  A Systematic Review of Recent Advances in Equine Influenza Vaccination.

Authors:  Romain Paillot
Journal:  Vaccines (Basel)       Date:  2014-11-14

10.  Model-based simulation and prediction of an antiviral strategy against influenza A infection.

Authors:  Kye-Yeon Hur; Joon-Young Moon; Seung-Hwan Kim; Joo-Yeon Yoo
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.